Lonza boosts Swiss antibody drug conjugate business

ZURICH (Reuters) – Lonza on Wednesday announced a deal with an unspecified customer for two new facilities for commercialization of antibody-drug conjugates at its Visp, Switzerland, site as the contract drug maker expands its work with the technology.

“Long-term collaboration with a global biopharma company will generate around 200 new jobs in the Visp biopark with operations expected to start from end-2022,” Lonza said in a statement.